相似文献
1
Induced pluripotent stem cells in cardiovascular drug discovery.
Circ Res. 2013 Feb 1;112(3):534-48. doi: 10.1161/CIRCRESAHA.111.250266.
2
Human-induced pluripotent stem cells in cardiovascular research: current approaches in cardiac differentiation, maturation strategies, and scalable production.
Cardiovasc Res. 2022 Jan 7;118(1):20-36. doi: 10.1093/cvr/cvab115.
3
A review of human pluripotent stem cell-derived cardiomyocytes for high-throughput drug discovery, cardiotoxicity screening, and publication standards.
J Cardiovasc Transl Res. 2013 Feb;6(1):22-30. doi: 10.1007/s12265-012-9423-2. Epub 2012 Nov 15.
4
The Application of Induced Pluripotent Stem Cells in Cardiac Disease Modeling and Drug Testing.
J Cardiovasc Transl Res. 2018 Oct;11(5):366-374. doi: 10.1007/s12265-018-9811-3. Epub 2018 May 29.
5
High throughput physiological screening of iPSC-derived cardiomyocytes for drug development.
Biochim Biophys Acta. 2016 Jul;1863(7 Pt B):1717-27. doi: 10.1016/j.bbamcr.2016.03.003. Epub 2016 Mar 4.
6
Cardiomyocytes from human pluripotent stem cells: From laboratory curiosity to industrial biomedical platform.
Biochim Biophys Acta. 2016 Jul;1863(7 Pt B):1728-48. doi: 10.1016/j.bbamcr.2015.10.014. Epub 2015 Oct 31.
7
Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes: The New Working Horse in Cardiovascular Pharmacology?
J Cardiovasc Pharmacol. 2021 Mar 1;77(3):265-266. doi: 10.1097/FJC.0000000000000981.
8
Human Induced Pluripotent Stem Cell-Derived Cardiac Progenitor Cells in Phenotypic Screening: A Transforming Growth Factor-β Type 1 Receptor Kinase Inhibitor Induces Efficient Cardiac Differentiation.
Stem Cells Transl Med. 2016 Feb;5(2):164-74. doi: 10.5966/sctm.2015-0114. Epub 2015 Dec 18.
9
An impedance-based approach using human iPSC-derived cardiomyocytes significantly improves in vitro prediction of in vivo cardiotox liabilities.
Toxicol Appl Pharmacol. 2017 Aug 15;329:121-127. doi: 10.1016/j.taap.2017.05.023. Epub 2017 May 22.
10
Induced pluripotent stem-cell-derived cardiomyocytes: cardiac applications, opportunities, and challenges.
Can J Physiol Pharmacol. 2017 Oct;95(10):1108-1116. doi: 10.1139/cjpp-2016-0726. Epub 2017 Mar 28.
引用本文的文献
1
Effect of iPS cell culture medium on the differentiation potential of induced cardiac tissues.
Sci Rep. 2025 Aug 3;15(1):28301. doi: 10.1038/s41598-025-13259-x.
2
Cardiomyocytes in Hypoxia: Cellular Responses and Implications for Cell-Based Cardiac Regenerative Therapies.
Bioengineering (Basel). 2025 Feb 6;12(2):154. doi: 10.3390/bioengineering12020154.
3
Advancing Human iPSC-Derived Cardiomyocyte Hypoxia Resistance for Cardiac Regenerative Therapies through a Systematic Assessment of In Vitro Conditioning.
Int J Mol Sci. 2024 Sep 5;25(17):9627. doi: 10.3390/ijms25179627.
4
Characterizing PFAS hazards and risks: a human population-based in vitro cardiotoxicity assessment strategy.
Hum Genomics. 2024 Sep 2;18(1):92. doi: 10.1186/s40246-024-00665-x.
5
Advancing Cardiovascular Drug Screening Using Human Pluripotent Stem Cell-Derived Cardiomyocytes.
Int J Mol Sci. 2024 Jul 21;25(14):7971. doi: 10.3390/ijms25147971.
6
In vitro to in vivo extrapolation from 3D hiPSC-derived cardiac microtissues and physiologically based pharmacokinetic modeling to inform next-generation arrhythmia risk assessment.
Toxicol Sci. 2024 Sep 1;201(1):145-157. doi: 10.1093/toxsci/kfae079.
7
Multi-lineage heart-chip models drug cardiotoxicity and enhances maturation of human stem cell-derived cardiovascular cells.
Lab Chip. 2024 Feb 13;24(4):869-881. doi: 10.1039/d3lc00745f.
8
Biotechnological advances and applications of human pluripotent stem cell-derived heart models.
Front Bioeng Biotechnol. 2023 Jul 25;11:1214431. doi: 10.3389/fbioe.2023.1214431. eCollection 2023.
9
Automated assessment of human engineered heart tissues using deep learning and template matching for segmentation and tracking.
Bioeng Transl Med. 2023 Apr 18;8(3):e10513. doi: 10.1002/btm2.10513. eCollection 2023 May.
10
Modelling premature cardiac aging with induced pluripotent stem cells from a hutchinson-gilford Progeria Syndrome patient.
Front Physiol. 2022 Nov 23;13:1007418. doi: 10.3389/fphys.2022.1007418. eCollection 2022.
本文引用的文献
1
Direct cardiac reprogramming: from developmental biology to cardiac regeneration.
Circ Res. 2013 Sep 13;113(7):915-21. doi: 10.1161/CIRCRESAHA.112.300625.
2
Progress in the reprogramming of somatic cells.
Circ Res. 2013 Feb 1;112(3):562-74. doi: 10.1161/CIRCRESAHA.111.249235.
3
Immunogenicity of pluripotent stem cells and their derivatives.
Circ Res. 2013 Feb 1;112(3):549-61. doi: 10.1161/CIRCRESAHA.111.249243.
4
Steps toward safe cell therapy using induced pluripotent stem cells.
Circ Res. 2013 Feb 1;112(3):523-33. doi: 10.1161/CIRCRESAHA.111.256149.
5
Functional screening identifies miRNAs inducing cardiac regeneration.
Nature. 2012 Dec 20;492(7429):376-81. doi: 10.1038/nature11739. Epub 2012 Dec 5.
6
Whole-genome microRNA screening identifies let-7 and mir-18 as regulators of germ layer formation during early embryogenesis.
Genes Dev. 2012 Dec 1;26(23):2567-79. doi: 10.1101/gad.200758.112. Epub 2012 Nov 14.
7
Cell model of catecholaminergic polymorphic ventricular tachycardia reveals early and delayed afterdepolarizations.
PLoS One. 2012;7(9):e44660. doi: 10.1371/journal.pone.0044660. Epub 2012 Sep 4.
8
High throughput measurement of Ca²⁺ dynamics for drug risk assessment in human stem cell-derived cardiomyocytes by kinetic image cytometry.
J Pharmacol Toxicol Methods. 2012 Nov-Dec;66(3):246-56. doi: 10.1016/j.vascn.2012.08.167. Epub 2012 Aug 25.
9
Small molecule-mediated TGF-β type II receptor degradation promotes cardiomyogenesis in embryonic stem cells.
Cell Stem Cell. 2012 Aug 3;11(2):242-52. doi: 10.1016/j.stem.2012.04.025.
10
Generation of patient-specific induced pluripotent stem cell-derived cardiomyocytes as a cellular model of arrhythmogenic right ventricular cardiomyopathy.
Eur Heart J. 2013 Apr;34(15):1122-33. doi: 10.1093/eurheartj/ehs226. Epub 2012 Jul 13.
Zotero 插件